Plain-English translation of NCT04697576 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach using (Flucelvax) injected directly into melanoma tumors. The goal is to see if this medication can train your immune system to recognize and attack cancer cells. You would receive injections over several weeks, and researchers will watch closely to see if tumors shrink and how your body responds.
Standard treatments for melanoma don't work for everyone, and some patients develop resistance over time. This trial explores whether this medication can boost the body's natural immune response against melanoma, potentially offering a new option—either alone for early-stage disease or combined with existing immunotherapy drugs for advanced cancer.
You likely qualify if…
You likely don't qualify if…
If you have early-stage melanoma (Cohort 1), you would receive one injection under the skin and two injections directly into your tumor over two weeks, then have surgery to remove the tumor about two weeks later. If you have advanced melanoma (Cohort 2), you would receive injections directly into your tumor roughly every two weeks for about three months while also taking standard immunotherapy drugs. Throughout the trial, you'll have blood tests, imaging, and possibly tumor biopsies so doctors can track how your immune system and cancer are responding.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States